Details for Patent: 9,585,868
Which drugs does patent 9,585,868 protect, and when does it expire?
Patent 9,585,868 protects MYTESI and is included in one NDA.
This patent has twenty-seven patent family members in twenty-one countries.
Summary for Patent: 9,585,868
| Title: | Methods and compositions for treating HIV-associated diarrhea | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | William Forbes, Enoch Bortey, Steven King, Pravin Chaturvedi | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Salix Pharmaceuticals Inc , Napo Pharmaceuticals Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US14/597,740 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Drug Patent 9,585,868: Crofelemer Claims, Exclusivity, Litigation Risk, and Patent LandscapeU.S. Patent No. 9,585,868 protects a specific method of using crofelemer, marketed as Mytesi, to treat HIV-associated or HAART-associated diarrhea. The principal claim requires an HIV-positive patient, a daily dose of approximately 250 mg or 125 mg twice daily, and treatment directed to ameliorating diarrhea symptoms. The patent does not broadly claim crofelemer, all diarrhea indications, or every dosage form. The strongest commercial coverage is the combination of indication, patient population, and dose. The principal design-around paths are to challenge those limitations, use a different dose or regimen, target a non-HIV indication, or contest the patent's validity and enforceability. What does U.S. Patent 9,585,868 protect?U.S. Patent 9,585,868 protects methods for administering crofelemer to HIV-positive patients with HIV-associated diarrhea or HAART-associated diarrhea. Claim 1 is the broadest independent claim:
The patent is a method-of-treatment patent, not a composition-of-matter patent. It does not claim the molecular structure of crofelemer or crofelemer generally as a pharmaceutical ingredient. The patent was granted on March 7, 2017. The listed assignee is Napo Pharmaceuticals, Inc., the developer associated with crofelemer and Mytesi.[1] How broad is independent claim 1?Claim 1 is narrower than a general crofelemer diarrhea claim but commercially meaningful because it tracks the approved HIV-associated diarrhea use and the standard Mytesi dosing regimen. Patient limitationThe patient must be HIV-positive. A patient with chronic noninfectious diarrhea, irritable bowel syndrome, cancer-treatment-associated diarrhea, or another unrelated condition would not fall within the express patient limitation of claim 1. The claim does not expressly require:
Claim 20 adds a narrower patient history requirement: the HIV-positive patient must have previously used protease inhibitors. Indication limitationThe claimed diarrhea must be HIV-associated or HAART-associated. This language creates an important causation and diagnosis issue. A generic manufacturer or prescriber could contest whether the diarrhea is caused by HIV infection, antiretroviral therapy, another medicine, an opportunistic infection, diet, or an unrelated gastrointestinal condition. The patent does not claim all uses of crofelemer for diarrhea. Its scope is tied to the HIV and HAART populations identified in the claims. Dose limitationClaim 1 covers either:
The word "about" provides some numerical flexibility, but it does not eliminate the dose limitation. A materially different daily dose may avoid literal infringement, although the doctrine of equivalents could create residual risk depending on the facts. The claim also does not expressly require tablets, capsules, a particular excipient system, or a particular release profile. A product supplied in a different dosage form could still infringe if it is used in the claimed manner. What do the dependent claims add?Claims 2 through 19 add treatment-duration, response, symptom, and patient-profile limitations. They do not expand claim 1. Each is narrower than the claim from which it depends.
Claims 2, 3, 6, 7, 8, and 9 overlap substantially. That overlap is common in pharmaceutical method patents because different duration limitations preserve fallback positions if a broader claim is challenged. What symptoms are covered by Patent 9,585,868?Claim 12 identifies the principal symptom endpoints:
Claims 13 through 18 narrow these endpoints. The patent therefore covers more than a reduction in stool frequency. A treatment response based primarily on stool consistency, urgency, or fecal incontinence may fall within the dependent claims if the other claim 1 requirements are satisfied. The use of "baseline" in claim 17 indicates that symptom improvement is measured against the patient's pre-treatment condition. The claims do not, on their face, establish a single numerical threshold for every symptom endpoint. What is the scope of claim 20 for prior protease-inhibitor users?Claim 20 covers the same crofelemer dose and HIV-associated or HAART-associated diarrhea indication as claim 1, but requires that the patient previously used protease inhibitors. This claim has two effects:
Claim 20 does not appear to require that the patient currently use a protease inhibitor. The stated requirement is prior use. It also does not limit the claim to one protease inhibitor, one treatment duration, or one level of treatment failure. When does U.S. Patent 9,585,868 expire?The patent issued in 2017, but patent expiration is generally calculated from the relevant nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other USPTO events. The patent's expected term runs into 2029 based on its priority and filing history.[1][2] The legally operative expiration date should be determined from the USPTO Patent Center record and any Orange Book listing in effect for the relevant FDA product. An issued patent does not automatically create FDA marketing exclusivity for the entire patent term.
Mytesi was approved by the FDA in December 2012 for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS receiving antiretroviral therapy.[3] FDA approval does not itself establish that every later crofelemer use is patent-protected. What is the Orange Book status of crofelemer and Mytesi?The FDA Orange Book identifies patents submitted by an NDA holder for an approved drug. Orange Book status can change through patent-listing updates, expiration, delisting, or FDA administrative action.[2] For a crofelemer generic applicant, the relevant regulatory questions are:
A generic applicant that omits the patented indication may reduce induced-infringement exposure, but the risk depends on the proposed label, promotional conduct, prescribing patterns, and the scope of any remaining unexpired patents. What Paragraph IV challenges could affect crofelemer?A Paragraph IV certification would assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. For Patent 9,585,868, the most likely challenge theories would focus on the following issues. Anticipation and obviousnessA challenger could rely on earlier crofelemer publications, clinical studies, patents, or regulatory materials showing:
The key question would be whether the full claimed combination was disclosed in one reference for anticipation, or whether a skilled person would have found the claimed regimen obvious from the prior art. Written description and enablementThe patent contains multiple duration ranges and symptom-response outcomes. A challenger could argue that the specification does not adequately support the full breadth of those ranges or every claimed clinical response. Enablement risk would depend on whether the disclosure supports treatment across the full HIV-positive population, the claimed durations, and the claimed symptom categories without undue experimentation. IndefinitenessPotential pressure points include:
Courts generally interpret "about" in view of the specification and technical context. The strength of an indefiniteness challenge would depend on the patent's disclosed tolerances, dosing data, and measurement methods. Infringement proofMethod claims create a proof problem. A patent holder generally must establish that the accused product is used, directed, or induced to be used in the claimed manner. A product label that expressly recommends the claimed dose and indication can create substantial risk. A label that omits the patented use may reduce but not necessarily eliminate risk. What formulations are protected by this patent?Patent 9,585,868 does not expressly claim a particular formulation architecture in the claims provided. It claims administration of crofelemer at specified doses. Accordingly, the patent may reach multiple dosage forms if they deliver the claimed crofelemer dose for the claimed HIV-associated diarrhea indication. It does not, based on the supplied claims, require:
Separate crofelemer formulation, composition, botanical-extraction, or manufacturing patents could create additional barriers. Those rights must be analyzed independently from Patent 9,585,868. How strong is the patent estate for crofelemer?The estate is strongest where the commercial product, FDA label, and patent claim converge:
The patent is commercially stronger as a label and use patent than as a platform patent. Its value depends on whether a generic or competitor must market crofelemer for the HIV-associated diarrhea indication and whether the listed dose remains central to the product's clinical use. Which companies are challenging crofelemer exclusivity?A complete answer requires current FDA Orange Book records, ANDA Paragraph IV notices, PACER litigation records, and USPTO assignment and maintenance data. The claim text alone does not establish the identity of any challenger, settlement, or active infringement case. No challenger, settlement agreement, or litigation outcome should be inferred solely from the existence of Patent 9,585,868. A Paragraph IV notice is confidential until litigation is filed or otherwise becomes public. What generic launch risks exist for Mytesi?A generic launch could follow several pathways: Full-label challengeThe applicant includes the HIV-associated diarrhea use and certifies Paragraph IV against listed patents. This creates the clearest infringement dispute and could trigger Hatch-Waxman litigation and a 30-month stay under applicable conditions.[4] Carved-out labelThe applicant omits the patented indication through a Section viii statement or labeling carve-out. The commercial opportunity may be smaller if the HIV-associated diarrhea indication is the principal use protected by the patent. Post-expiration launchThe applicant waits for patent expiration or settlement-authorized entry. This reduces litigation exposure but delays market access. Dose or regimen distinctionA competitor could explore a materially different dosing regimen. That approach faces clinical, regulatory, and doctrine-of-equivalents risks and may not be commercially attractive if the approved regimen is the standard of care. Does crofelemer face biosimilar risk?No. Crofelemer is a botanical-derived small-molecule drug product, not a biologic subject to the biosimilar pathway under the Public Health Service Act. Competitive entry would generally involve an ANDA, a 505(b)(2) application, or a full NDA depending on the product's formulation, clinical reliance, and differences from Mytesi.[3][5] The main regulatory competition is therefore generic or follow-on small-molecule competition, not biosimilar substitution. What litigation and settlement issues matter?The critical litigation issues are:
A settlement could permit entry before patent expiration, but its commercial effect would depend on the entry date, product restrictions, authorized-generic terms, and any Federal Trade Commission review. How does Patent 9,585,868 compare with broader drug patents?
The patent's claim breadth is concentrated rather than general. It can materially delay an HIV-diarrhea generic while leaving other crofelemer indications and noninfringing development programs open. Key Takeaways
FAQs About U.S. Patent 9,585,868Is Patent 9,585,868 a patent on Mytesi itself?No. It is a method patent covering specified use of crofelemer in HIV-positive patients with HIV-associated or HAART-associated diarrhea. Does the patent cover crofelemer for irritable bowel syndrome?Not based on the supplied claims. The claims require an HIV-positive patient and HIV-associated or HAART-associated diarrhea. Can a generic use a different crofelemer dose?A materially different dose may avoid literal infringement of claim 1, but regulatory approval, clinical efficacy, and potential equivalents issues remain relevant. Does prior protease-inhibitor use apply to every claim?No. It is expressly required by claim 20. Claim 1 does not include that prior-use limitation. Is a crofelemer generic automatically blocked until 2029?No. Market entry depends on the complete Orange Book listing, other relevant patents, the generic label, any Paragraph IV litigation, settlements, and the applicable expiration dates. References
More… ↓ |
Drugs Protected by US Patent 9,585,868
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Napo Pharms Inc | MYTESI | crofelemer | TABLET, DELAYED RELEASE;ORAL | 202292-001 | Dec 31, 2012 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,585,868
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011320155 | ⤷ Start Trial | |||
| Brazil | 112013010774 | ⤷ Start Trial | |||
| Canada | 2816416 | ⤷ Start Trial | |||
| China | 103370101 | ⤷ Start Trial | |||
| China | 107595836 | ⤷ Start Trial | |||
| Colombia | 6771411 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
